Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (NEURO-TTR Study)

Next Previous
X
Search
Trial Profile

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (NEURO-TTR Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloid polyneuropathy; Familial amyloid neuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms NEURO-TTR
  • Sponsors Ionis Pharmaceuticals

    • Most Recent Events

    • 01 Sep 2022 Results assessing patient subgroups exhibiting the greatest health-related quality of life (HRQL) benefit from inotersen treatment published in the Muscle and Nerve
    • 01 Jan 2022 Results of a responder analysis for neuropathic impairment and quality-of-life assessment published in the Journal of Neurology
    • 01 Jan 2021 Results ofa pooled analysis ( of data extracted from Neuro-TTR and APOLLO studies) assessing Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy, published in the Expert Opinion on Pharmacotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top